Oxycodone: a pharmacological and clinical review.

Area of Science:

• Pharmacology
• Pain Management
• Opioid Analgesics

Background:

• Oxycodone is a semi-synthetic opioid agonist with activity on mu, kappa, and delta receptors.
• It exhibits a 1:2 equivalence with morphine and has a plasma half-life of 3-5 hours.
• Oral bioavailability ranges from 60-87% with 45% plasma protein binding.

Purpose of the Study:

• To review the pharmacological properties, clinical efficacy, and safety profile of oxycodone.
• To compare oxycodone with morphine for pain management, particularly in cancer pain.
• To outline administration guidelines and potential side effects of oxycodone formulations.

Main Methods:

• Review of existing literature on oxycodone's pharmacokinetic and pharmacodynamic properties.
• Comparison of clinical efficacy and toxicity data against morphine.
• Analysis of metabolism, receptor binding, and neuronal effects.

Main Results:

• Oxycodone demonstrates similar clinical efficacy to morphine in cancer pain treatment (1:1.5-2 ratio).
• Its metabolism is more predictable than morphine, facilitating easier titration.
• Long-term administration may be associated with less toxicity compared to morphine.

Conclusions:

• Oxycodone is a viable and effective opioid analgesic for moderate to severe pain.
• Controlled-release oxycodone offers sustained pain relief with a predictable pharmacokinetic profile.
• Potential for reduced toxicity compared to morphine warrants further investigation, possibly through combination therapy.